Search Results - "Meinicke, Thomas"

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes by Yabe, Daisuke, Shiki, Kosuke, Suzaki, Keiko, Meinicke, Thomas, Kotobuki, Yutaro, Nishida, Kenichiro, Clark, Douglas, Yasui, Atsutaka, Seino, Yutaka

“…IntroductionElderly people (≥65 years) with type 2 diabetes mellitus (T2DM) are becoming increasingly prevalent, notably in Japan. As cardiovascular (CV) risk…”
Get full text

Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects by Macha, Sreeraj, PhD, Brand, Tobias, MD, Meinicke, Thomas, MD, Link, Jasmin, MS, Broedl, Uli C., MD

“…Abstract Purpose This study was undertaken to compare the steady-state pharmacokinetic and pharmacodynamic properties of empagliflozin 5 mg twice daily (BID)…”
Get full text

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial by Rosenstock, Julio, Kahn, Steven E, Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A, Woerle, Hans J, Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T, von Eynatten, Maximilian, McGuire, Darren K, Marx, Nikolaus

“…IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4…”
Get full text

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY ) by Yabe, Daisuke, Shiki, Kosuke, Homma, Gosuke, Meinicke, Thomas, Ogura, Yuji, Seino, Yutaka

“…Abstract Aim Use of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) for glycaemic control is increasing in individuals with type 2 diabetes (T2D) for…”
Get full text

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial by HÄRING, Hans-Ulrich, MERKER, Ludwig, SEEWALDT-BECKER, Elke, WEIMER, Marc, MEINICKE, Thomas, BROEDL, Uli C, WOERLE, Hans J

“…To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes. Patients with HbA1c levels of…”
Get full text

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes by Hadjadj, Samy, Rosenstock, Julio, Meinicke, Thomas, Woerle, Hans J, Broedl, Uli C

“…This study compared the efficacy and safety of initial combinations of empagliflozin + metformin with empagliflozin and metformin monotherapy in patients with…”
Get full text

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial by HÄRING, Hans-Ulrich, MERKER, Ludwig, SEEWALDT-BECKER, Elke, WEIMER, Marc, MEINICKE, Thomas, WOERLE, Hans J, BROEDL, Uli C

“…To investigate the efficacy and tolerability of empagliflozin as add-on to metformin and sulfonylurea in patients with type 2 diabetes. Patients inadequately…”
Get full text

Front Cover by Yabe, Daisuke, Shiki, Kosuke, Homma, Gosuke, Meinicke, Thomas, Ogura, Yuji, Seino, Yutaka

Get full text

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial by Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E, Kahn, Steven E, Marx, Nikolaus, Alexander, John H, Pencina, Michael, Toto, Robert D, Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T, von Eynatten, Maximilian, McGuire, Darren K

“…IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4)…”
Get full text

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial by Ferreira, João Pedro, Inzucchi, Silvio E., Mattheus, Michaela, Meinicke, Thomas, Steubl, Dominik, Wanner, Christoph, Zinman, Bernard

“…Aim To evaluate the effect of empagliflozin on uric acid (UA) levels, antigout medication and gout episodes in the EMPA‐REG OUTCOME trial (NCT01131676)…”
Get full text

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial by Groop, Per‐Henrik, Cooper, Mark E., Perkovic, Vlado, Hocher, Berthold, Kanasaki, Keizo, Haneda, Masakazu, Schernthaner, Guntram, Sharma, Kumar, Stanton, Robert C., Toto, Robert, Cescutti, Jessica, Gordat, Maud, Meinicke, Thomas, Koitka‐Weber, Audrey, Thiemann, Sandra, von Eynatten, Maximilian

“…Aims The MARLINA‐T2D study (ClinicalTrials.gov, NCT01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to…”
Get full text

Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial by Yang, Wenying, Xu, Xiangjin, Lei, Tao, Ma, Jianhua, Li, Ling, Shen, Jie, Ye, Binqi, Zhu, Sandy, Meinicke, Thomas

“…This 24‐week, double‐blind, placebo‐controlled, phase III trial evaluated the efficacy and safety of linagliptin in 206 Chinese patients with inadequately…”
Get full text

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA by McGuire, Darren K, Alexander, John H, Johansen, Odd Erik, Perkovic, Vlado, Rosenstock, Julio, Cooper, Mark E, Wanner, Christoph, Kahn, Steven E, Toto, Robert D, Zinman, Bernard, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T, von Eynatten, Maximilian, Marx, Nikolaus

“…Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular…”
Get full text

Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study by Ji, Linong, Lu, Yibin, Li, Qifu, Fu, Liujun, Luo, Yong, Lei, Tao, Li, Ling, Ye, Shandong, Shi, Bimin, Li, Xiyan, Meinicke, Thomas

“…Aim To evaluate the efficacy and safety of empagliflozin in combination with insulin ± oral antidiabetic drugs (OADs) over 24 weeks, in Chinese patients with…”
Get full text

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial by Perkovic, Vlado, Toto, Robert, Cooper, Mark E, Mann, Johannes F E, Rosenstock, Julio, McGuire, Darren K, Kahn, Steven E, Marx, Nikolaus, Alexander, John H, Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, von Eynatten, Maximillian, George, Jyothis T, Johansen, Odd Erik, Wanner, Christoph

“…Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed…”
Get full text

P-232: Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications by Neutel, Joel M., Klein, Christiane, Meinicke, Thomas W., Schumacher, Helmut

“…This open-label, multicenter, extension study assessed the efficacy and tolerability of telmisartan 80 mg administered alone or with hydrochlorothiazide (HCTZ)…”
Get full text

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes by Haering, Hans-Ulrich, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Meinicke, Thomas, Woerle, Hans J, Broedl, Uli C

“…Highlights • Empagliflozin or placebo was given to patients with type 2 diabetes for ≥76 weeks. • Patients received study drug as add-on to metformin plus…”
Get full text

Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety by Freytag, Frank, Holwerda, Nicolaas J, Karlberg, Bengt E, Meinicke, Thomas W, Schumacher, Helmut

“…This multicentre, open-label extension study to four controlled trials involved 888 patients with mild-to-moderate primary hypertension. Patients received…”
Get more information

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria by Cooper, Mark E, Perkovic, Vlado, Groop, Per-Henrik, Hocher, Berthold, Hehnke, Uwe, Meinicke, Thomas, Koitka-Weber, Audrey, van der Walt, Sandra, von Eynatten, Maximilian

“…OBJECTIVE:Concomitant treatment with angiotensin-converting enzyme (ACE) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors is increasingly common…”
Get full text

Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial by Ledesma, Gilbert, Umpierrez, Guillermo E., Morley, John E., Lewis‐D'Agostino, Diane, Keller, Annett, Meinicke, Thomas, Walt, Sandra, von Eynatten, Maximilian

“…Aim To assess the addition of linagliptin as an alternative to insulin uptitration in older people with type 2 diabetes on stable insulin therapy. Materials…”
Get full text